NCT03223610 2026-04-20
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
22 trialsNCT04544592 2026-04-20
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
Phase 1/2 Recruiting
NCT04491370 2026-04-15
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
Phase 1/2 Recruiting
NCT06395103 2026-04-13
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07069699 2026-04-13
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT07109219 2026-04-06
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT06533579 2026-03-30
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT07134088 2026-03-30
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Recruiting
NCT05674175 2026-03-27
Co-administration of CART22-65s and huCART19 for B-ALL
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT05442515 2026-03-12
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06287229 2026-02-17
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06580301 2026-02-06
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2 Recruiting
NCT06137118 2026-01-16
SYRUS
AstraZeneca
Phase 1/2 Recruiting
NCT05480449 2025-12-26
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT01371630 2025-12-18
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04150497 2025-09-09
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Phase 1/2 Recruiting
NCT05667506 2025-08-12
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd.
Phase 1/2 Recruiting
NCT06735495 2024-12-16
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT06635330 2024-10-10
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Kara Yakhteh Tajhiz Azma Company
Phase 1/2 Recruiting
NCT06503094 2024-07-16
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT05310591 2024-05-29
CAPTiRALL
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Recruiting